Annual Meeting

Using bacteria to clean the environment

Núria  Negrão
April 28, 2021

In recent years, concerns have heightened about increasing amounts of drugs in the environment, particularly in water. While the impact of this environmental pollution is not well understood, some evidence indicates that these drugs may be entering the food chain. Researchers  believe that most of the drugs that end up in fresh water first accumulate at wastewater treatment facilities. Therefore, there is a need to eliminate the drugs at these facilities.

Ashley Robinson, a senior biochemistry major at Hamline University who plans to start graduate school in the fall, started doing research in her sophomore year. She is presenting a poster at the 2021 ASBMB Annual Meeting on this topic, the third research project she has worked on with Betsy Martínez–Vaz.

Kathryn Malody
Ashley Robinson works in the biological safety hood at the Martínez–Vaz lab.

The researchers’ goal was to find bacteria that break down metformin, a drug commonly used to treat diabetes in the U.S. and around the world. Little research has been done on the impact of pollution with metformin and its byproduct, guanylurea, which are not fully metabolized by humans and thus are excreted into wastewater systems. “We consider them to be emerging pollutants,” Robinson said.

Ashley Robinson & James Aukema
This graphic represents the topics of Robinson’s research. With increasing prescription of the Type 2 diabetes drug metformin (top), both metformin and its predominant metabolite, guanylurea (bottom), are water pollutants of emerging concern worldwide. The researchers recently isolated a strain of Pseudomonas that can completely degrade guanylurea from a wastewater treatment facility (middle). They identified and characterized a guanylurea-degrading enzyme, guanylurea hydrolase.

Studies have demonstrated the potential for metformin to disrupt some hormones, she explained. The drug  is considered an endocrine disruption agent in some small fishes, and guanylurea has been shown to interfere with the nitrogen cycle in soil. Little is known about its bioaccumulation potential.

“Can these molecules pass up the food chain?” Robinson said. “That is one concern that we have.”

The research team collected samples at a local wastewater treatment facility from several stages of the treatment process. The bacteria in the samples were then grown in the lab under limiting conditions, meaning the bacteria were not given all the nutrients they needed. In this case, their only source of nitrogen was metformin, so most of the bacteria that survived were species that could use metformin as a nitrogen source. The team then used metagenomics to identify the enzymes involved in the breakdown of guanylurea and its transformation product guanidine. They identified three enzymes: guanylurea hydrolase, carboxyguanidine deiminase and allophanate hydrolase.

Robinson and her colleagues are now working to identify the enzyme that breaks down metformin in the initial step that forms guanylurea. They hope the enzymes they find could be used to break down metformin and guanylurea at wastewater treatment facilities, keeping these pollutants out of freshwater systems.


Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Núria  Negrão

Núria Negrão is a medical writer and editor at Cactus Communications.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Melissa Moore to speak at ASBMB 2025
ASBMB Annual Meeting

Melissa Moore to speak at ASBMB 2025

April 2, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.

 A new kind of stem cell is revolutionizing regenerative medicine
Feature

A new kind of stem cell is revolutionizing regenerative medicine

April 1, 2025

Induced pluripotent stem cells are paving the way for personalized treatments to diabetes, vision loss and more. However, scientists still face hurdles such as strict regulations, scalability, cell longevity and immune rejection.

Engineering the future with synthetic biology
ASBMB Annual Meeting

Engineering the future with synthetic biology

March 31, 2025

Learn about the ASBMB 2025 symposium on synthetic biology, featuring applications to better human and environmental health.

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance
Webinar

Scientists find bacterial ‘Achilles’ heel’ to combat antibiotic resistance

March 28, 2025

Alejandro Vila, an ASBMB Breakthroughs speaker, discussed his work on metallo-β-lactamase enzymes and their dependence on zinc.

Host vs. pathogen and the molecular arms race
ASBMB Annual Meeting

Host vs. pathogen and the molecular arms race

March 28, 2025

Learn about the ASBMB 2025 symposium on host–pathogen interactions, to be held Sunday, April 13 at 1:50 p.m.

Richard Silverman to speak at ASBMB 2025
ASBMB Annual Meeting

Richard Silverman to speak at ASBMB 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the ASBMB annual meeting to be held April 12-15 in Chicago.